# Applaud Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/applaud-medical

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.applaudmedical.com
- Total disclosed funding: $24M
- Latest round: Series B (Feb 11, 2021)
- Investors on record: 1

## About

Applaud Medical, Inc. specializes in innovative technologies for kidney stone management, focusing on the development of the Enhanced Lithotripsy System to improve patient outcomes through minimally invasive treatments.Founded in 2014 in San Francisco, US, Applaud Medical, Inc. is dedicated to advancing treatment options for urinary stone disease. The company raised USD 12.53 mn in Series B funding on February 11, 2021, from Kairos Ventures, bringing the total amount raised to USD 12.53 mn and its current valuation to USD 55.625 mn. The company was co-founded by Claire Mills and Thomas Kenny, with Paul Molloy serving as the CEO.Applaud Medical offers a pioneering treatment system for urinary stone disease, centered around its Enhanced Lithotripsy System (ELS). This investigational technology employs low-pressure ultrasound combined with calcium-seeking microbubbles to create millions of micro-jets that effectively fragment kidney stones. The procedure is designed for outpatient clinics or rural healthcare settings, enhancing patient safety and comfort while streamlining care processes.Applaud Medical generates revenue through partnerships with healthcare facilities and outpatient clinics utilizing its Enhanced Lithotripsy System. The business model includes direct sales of the ELS to medical institutions, alongside training and support services for healthcare providers. Revenue transactions occur through structured agreements outlining the use of the technology, which may be offered as a standalone service or integrated into existing urological treatment protocols.Applaud Medical plans to leverage its recent Series B funding of USD 12.53 mn to enhance the development of its Enhanced Lithotripsy System and expand into new markets, focusing on international healthcare providers. The company is targeting specific regions for expansion, aiming to increase its reach significantly by the end of 2023.

## Funding rounds

- Series B, Feb 11, 2021, $13M — Kairos Ventures
- Series B, Feb 11, 2020, $11M — Kairos Ventures

## Investors

- Kairos Ventures (https://capitalatlas.ai/funds/kairos-ventures) — Series B